Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 16/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20186959 | 0.87 | FGFR4 (0.44) | MAPK3EGFRBTK | |
| SCHEMBL20186913 | 0.74 | SRC (0.45) | FYNSRCEGFR | |
| SCHEMBL20186909 | 0.73 | FGFR4 (0.41) | MAPK3EGFRMAPK1BTK | |
| SCHEMBL20186946 | 0.73 | MAPK3 (0.44) | MAPK3EGFR | |
| SCHEMBL20186911 | 0.72 | FGFR4 (0.42) | SRCEGFRBTK | |
| SCHEMBL20186914 | 0.70 | FGFR4 (0.40) | SRCEGFR | |
| SCHEMBL20186929 | 0.70 | FGFR4 (0.54) | MAPK3 | |
| SCHEMBL946592 | 0.69 | KDM4E (0.66) | BTK | |
| SCHEMBL21894350 | 0.69 | MAPK3 (0.49) | MAPK3FYNSRCMAPK1MAP2K1 | |
| SCHEMBL27051832 | 0.68 | AKT1 (0.54) | MAPK3EGFRMAPK1MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040803-B2 | 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-08-07 | — | — | US | disclosed |
| US-10040803-B2 | 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-08-07 | — | — | US | disclosed |
| US-10040803-B2 | 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-08-07 | — | — | US | disclosed |
| US-20180148459-A1 | 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-05-31 | — | — | US | disclosed |
| US-20180148459-A1 | 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-05-31 | — | — | US | disclosed |
| US-20180148459-A1 | 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148459-A1 | 4-((2-ACRYLAMIDOPHENYL)AMINO)THIENO[3,2-D]PYRIMIDINE-7-CARBOXAMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK2, CDK2AP2, CDK2AP1 | MAPK3 139/4885FYN 915/4885SRC 309/4885 |
| US-10040803-B2 | 4-((2-acrylamidophenyl)amino)thieno[3,2-D]pyrimidine-7-carboxamide derivatives as protein kinase inhibitors | CDK2, CDK2AP2, CDK2AP1 | MAPK3 139/4885FYN 915/4885SRC 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.